中信证券股份有限公司 关于深圳市昌红科技股份有限公司及子公司向金融机构申 请综合授信额度及对外担保额度预计的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳市昌红 科技股份有限公司（以下简称"昌红科技"或"公司"） 2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》等有关法律法规规定，对公司及子公司向金融机构申请综 合授信额度及对外担保额度预计事项进行了核查，具体核查情况如下： 一、申请综合授信额度及对外担保额度预计的情况概述 为落实公司发展战略，满足公司及子公司（包括全资子公司和控股子公司） 日常经营及业务发展的需要，公司及子公司拟向银行等金融机构申请总额不超过 人民币 100,000.00 万元综合授信额度，授信品种包括但不限于流动资金贷款、固 定资产贷款、项目贷款、承兑汇票、信用证、票据贴现、金融衍生品等综合业务。 上述授信额度不等同于实际融资金额，公司及子公司将根据具体的授信条件选择 最有利于公司的金融机构，具体业务品种、授信额 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 249,088,234.83, representing a 6.70% increase compared to CNY 233,436,775.43 in the same period last year[5]. - Net profit attributable to shareholders decreased by 28.94% to CNY 17,737,257.55 from CNY 24,959,889.53 year-on-year[5]. - Basic and diluted earnings per share both fell by 40.00% to CNY 0.03 from CNY 0.05[5]. - Total operating revenue for the current period reached ¥249,088,234.83, an increase of 6.1% compared to ¥233,436,775.43 in the previous period[22]. - Net profit for the current period was ¥12,351,745.99, a decrease of 42.0% from ¥21,343,409.98 in the previous period[23]. - Total comprehensive income for the period was CNY 11,901,755.69, compared to CNY 17,037,947.82 in the previous period, reflecting a decrease of approximately 30.5%[24]. - The total comprehensive income attributable to the parent company was CNY 17,287,267.25, compared to CNY 20,654,427.37, a decrease of approximately 16.5%[24]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 51,840,759.82, down 15.73% from CNY 61,518,221.92 in the previous year[5]. - Cash inflow from operating activities totaled CNY 310,568,421.52, an increase of 10.3% from CNY 281,404,992.43 in the previous period[26]. - Cash outflow from investing activities was CNY 479,889,621.42, compared to CNY 351,811,958.58, representing an increase of approximately 36.4%[27]. - Net cash flow from financing activities was CNY 41,183,458.85, a significant improvement from a negative CNY 6,941,433.43 in the previous period[27]. - The company reported a net cash decrease of CNY 4,640,200.42 for the period, compared to a decrease of CNY 58,788,544.62 in the previous period[27]. - Cash and cash equivalents at the end of the period were CNY 321,623,308.87, down from CNY 641,384,957.64, indicating a decrease of about 50%[27]. Assets and Liabilities - Total assets increased by 1.95% to CNY 2,512,578,592.51 compared to CNY 2,464,470,524.07 at the end of the previous year[5]. - Current liabilities totaled ¥321,416,802.48, an increase of 12.8% from ¥284,914,336.13 in the previous period[21]. - Non-current liabilities remained stable at ¥520,532,051.76, slightly down from ¥520,628,381.36 in the previous period[21]. - The company's equity attributable to shareholders rose by 1.05% to CNY 1,648,197,990.05 from CNY 1,631,110,546.79[5]. - The company's equity attributable to shareholders increased to ¥1,648,197,990.05, up from ¥1,630,910,546.79 in the previous period[21]. Shareholder Information - The largest shareholder, Li Huanchang, holds 202,696,900 shares, representing 38.06% of the total share capital, with 152,022,675 shares pledged[15]. - The top 10 shareholders collectively hold 202,959,400 shares, accounting for 38.11% of the total share capital[15]. - The company has a total of 163,811,713 shares under lock-up conditions, with no shares released during the current period[17]. - There are no changes in the number of shares lent or returned by the top shareholders due to margin trading activities[15]. Other Income and Expenses - Other income decreased by 36.52% to CNY 315.74 from CNY 497.38, primarily due to reduced government subsidies[11]. - Investment income turned negative at CNY -49.61, a decline of 133.53% from CNY 147.99, mainly due to losses from an associated company[11]. - Total operating costs increased to ¥233,383,776.18, up 8.7% from ¥214,740,980.94 in the previous period[22]. - Research and development expenses for the current period were ¥12,614,904.31, compared to ¥12,010,175.12 in the previous period, indicating a 5.0% increase[23]. Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in the current report[18]. - The company has not reported any significant mergers or acquisitions in the current period[18].

Financial Performance - The company's operating revenue for 2024 reached ¥1,038,898,133.44, an increase of 11.56% compared to ¥931,271,438.81 in 2023[19]. - Net profit attributable to shareholders for 2024 was ¥101,963,473.13, representing a significant increase of 222.11% from ¥31,655,146.81 in 2023[19]. - The net profit after deducting non-recurring gains and losses was ¥85,544,955.85, up 348.15% from ¥19,088,608.07 in 2023[19]. - The basic earnings per share for 2024 was ¥0.19, a 216.67% increase from ¥0.06 in 2023[19]. - The total assets at the end of 2024 were ¥2,464,270,524.07, a decrease of 3.57% from ¥2,555,436,436.76 at the end of 2023[19]. - The weighted average return on equity for 2024 was 6.23%, up from 2.27% in 2023[19]. - The net cash flow from operating activities for 2024 was ¥173,916,844.05, a decrease of 10.00% compared to ¥193,243,973.94 in 2023[19]. - The company reported a total of ¥16,418,517.28 in non-recurring gains for 2024, compared to ¥12,566,538.74 in 2023[25]. - The company's total revenue for the reporting period was 1,038.90 million RMB, an increase of 11.56% compared to the same period last year[83]. - Net profit attributable to shareholders was 101.96 million RMB, representing a significant growth of 222.11% year-over-year[83]. - Basic earnings per share rose to 0.19 RMB, reflecting a 216.67% increase compared to the previous year[83]. Dividend Distribution - The company plans to distribute a cash dividend of 0.75 RMB per 10 shares to all shareholders, based on a total of 532,508,690 shares[5]. - Cumulative cash dividends for 2024 are projected to be 718.89 million yuan, accounting for 70.50% of the net profit attributable to shareholders[170]. Governance and Compliance - The company has a comprehensive governance structure, with all board members present for the report's approval, ensuring accountability and transparency[5]. - The financial report is guaranteed to be true, accurate, and complete by the company's leadership, including the chairman and accounting heads[5]. - The company is subject to regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, ensuring compliance with national financial laws[12]. - The company emphasizes technological innovation and R&D strength, investing in new technologies and materials to maintain industry-leading product performance and quality[76]. - The company has established a market value management system to enhance its market management practices and protect investor rights[168]. - The company has complied with all relevant laws and regulations regarding corporate governance, with no significant discrepancies identified[185]. Market and Industry Insights - The company is engaged in the specialized equipment manufacturing industry, focusing on medical devices, smart manufacturing, and semiconductor materials[28]. - The medical device industry is experiencing rapid growth driven by healthcare system reforms and increasing domestic demand for high-quality medical equipment[35]. - The global medical device market size in 2023 was $582.6 billion, with a five-year compound growth rate of approximately 6.37%[30]. - China's medical device market size reached 1.27 trillion yuan in 2023, with a compound annual growth rate exceeding 10%[30]. - The "14th Five-Year Plan" emphasizes the need for innovation in medical devices and pharmaceuticals, aiming to strengthen the public health system[30]. - The company is focusing on expanding its presence in the assisted reproductive technology sector with innovative tools like embryo culture dishes and sperm collection cups[59]. Research and Development - The company has established a comprehensive R&D system, including the Guangdong Precision Injection Mold Engineering Technology Research Center and the Shanghai Emerging Medical Devices and Life Sciences R&D Center, focusing on industry technology hotspots and challenges[67]. - The company focuses on independent R&D, enhancing precision mold manufacturing, automation production integration, and precision injection molding technology, continuously upgrading processing technology and design capabilities[66]. - Continuous investment in R&D and product innovation is a key focus, particularly in the development of high-performance materials for medical consumables[80]. - The company has seven products under research, with several entering the "small batch and verification" stage at domestic mainstream wafer manufacturers[88]. Strategic Initiatives - The company has plans for market expansion and new product development in the specialized equipment sector[28]. - The company aims to leverage its R&D capabilities to develop new technologies that address emerging healthcare challenges and improve patient outcomes[60]. - The company is investing in smart manufacturing technologies to enhance production efficiency and product quality[62]. - The company plans to enhance its global industrial chain layout and increase its production capacity in the high-end medical device sector, with a focus on expanding its market presence in Southeast Asia[146][148]. Financial Management - The company has maintained good management of raised funds, ensuring compliance with the three-party supervision agreement with banks and sponsors[131]. - The company has established dedicated accounts for the management of raised funds, ensuring strict approval processes for their use[131]. - The company has reported a total of 776,697.55 yuan in surplus funds from the high-end medical equipment and consumables production line expansion project, which will be permanently used to supplement working capital[134]. - The company has achieved a cumulative investment of 9.88 million in specific projects, with 100% of the investment completed by the end of the reporting period[132]. Operational Efficiency - The company is enhancing its information technology infrastructure to improve management efficiency and reduce costs[91]. - The production is customer demand-oriented, with production plans based on annual sales targets and actual order volumes, ensuring efficient resource allocation[71]. - The company has a complete after-sales service team, providing high-quality support, product upgrades, and technical training to maintain long-term customer relationships[72]. Talent and Human Resources - The company has a talent pool of over 500 individuals across R&D, production, sales, and management, focusing on enhancing high-end talent reserves[150]. - The company is actively recruiting high-quality talent and optimizing its internal control systems to address management risks associated with business expansion[165]. Shareholder Engagement - The company held 3 shareholder meetings in 2024, ensuring equal rights for all shareholders and protecting the interests of minority investors[174]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with legal regulations[179].

昌红科技（300151）公告，2025年第一季度营业收入2.49亿元，同比增长6.70%。净利润1773.73万元， 同比下降28.94%。 ...

此次颁奖典礼上，罗氏授予昌红科技"五载精诚协作，共筑诊断未来"奖项，以表彰双方在过去五年合作 中所做出的卓越贡献。罗氏诊断仪器制造全球负责人Joerg Spielmann先生在颁奖现场表示，罗氏拥有 120多年的历史，与昌红科技的合作在过去五年尤为重要。他再次肯定了昌红科技的努力，并期待双方 在未来能够进行更紧密的合作。 日前，罗氏与昌红科技（300151）在浙江柏明胜医疗产业园举办五周年合作颁奖典礼。此次活动不仅是 对双方五年来紧密合作的高度肯定，更是对未来携手共进的美好展望。 罗氏诊断仪器制造全球负责人Joerg Spielmann、亚太区仪器本土化项目负责人Laura Bischoff、罗氏诊断 仪器制造苏州负责人Ben Fu、罗氏苏州采购总监Jason Liu，与昌红科技董事长李焕昌、柏明胜医疗总经 理罗红志、副总经理孙章辉、营销总监陈杰泉等领导共同出席本次活动。 双方团队回顾合作历程，昌红科技凭借其在精密模具和注塑成型领域的核心技术，为罗氏提供了高品质 的产品，取得罗氏的高度认可，通过稳定的供应链和高质量的产品，为双方的合作提供了坚实保障。昌 红科技表示，公司将不断优化风险教育、沉淀技术经验，并通过 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2025-010 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司关于 控股股东、实际控制人部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）近日接到公司控股股东、 实际控制人李焕昌先生的通知，获悉李焕昌先生将其所持有的公司部分股份办理 了质押及解除质押手续，具体事项如下： 一、股东股份质押及后续进展基本情况 | | 李焕昌 | | | 名称 | 股东 | | | --- | --- | --- | --- | --- | --- | --- | | | 是 | | 一致行动人 | 大股东及其 | 股东或第一 | 是否为控股 | | 000 | | 63,560, | （股） | 押数量 | | 本次质 | | | 31.36 | | （%） | 比例 | 持股份 | 占其所 | | | 11.94 | | （%） | 1比例 | 总股 ...

证券代码：300151 证券简称：昌红科技 公告编号：2025-009 债券代码：123109 债券简称：昌红转债 深圳市昌红科技股份有限公司 关于 2025 年第一季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 票面总金额为 459,529,700.00 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，深圳市昌红科技股份 有限公司（以下简称"公司"）现将 2025 年第一季度可转换公司债券（以下简称 "昌红转债"或"可转债"）转股及公司总股本变化情况公告如下： 经中国证券监督管理委员会出具的《关于同意深圳市昌红科技股份有限公司 向不特定对象发行可转换公司债券注册的批复》（证监许可〔2021〕609 号）核 准，公司本次可转换公司债券的发行规模为 46,000.00 万元，发行数量为 460.00 万张，每张面值 100.00 元，募集资金总额 46,000.00 万元，扣除本次发行募集资 金承销保荐费及其他发行费用（不含税）1,226 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、"昌红转债"（债券代码: 123109）转股期为 2021 年 10 月 8 日至 2027 年 3 月 31 日；初始转股价格为 28.26 元/股，最新转股价格为 26.79 元/股。 2、2025 年第一季度，"昌红转债"因转股减少 200.00 元（2 张），转股数量为 7 股。 3、截至 2025 年第一季度末，公司剩余可转债为 4,595,297 张，剩余可转债 票面总金额为 459,529,700.00 元人民币。 | 证券代码：300151 | 证券简称：昌红科技 | 公告编号：2025-009 | | --- | --- | --- | | 债券代码：123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于 2025 年第一季度可转债转股情况的公告 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，深圳市昌红科技股份 有限公司（以下简称"公司"）现将 2025 年第一季度可转换公司债券 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2025-008 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司 特别提示 1、"昌红转债"（债券代码：123109）将于 2025 年 4 月 1 日按面值支付第四 年利息，每 10 张"昌红转债"（面值 1,000.00 元）利息为 15.00 元（含税）。 关于可转换公司债券 2025 年付息的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、债权登记日：2025 年 3 月 31 日 3、除息日：2025 年 4 月 1 日 4、付息日：2025 年 4 月 1 日 5、本次付息期间及票面利率：计息期间为 2024 年 4 月 1 日至 2025 年 3 月 31 日，票面利率为 1.50%。 6、"昌红转债"本次付息的债权登记日为 2025 年 3 月 31 日，截至 2025 年 3 月 31 日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司深圳分 公司（以下简称"中国结算深圳 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2025-007 | | --- | --- | --- | | 债券代码: 123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于公司以自有资产抵押向银行申请借款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 公司与中国银行签署的《固定资产借款合同》，约定贷款期限为 5 年（借款期限自实际提款日起算）超 过公司第六届董事会第八次会议、2023 年年度股东大会决议已审批的授信时长。若预计超过已审批授信 时长，公司将召开董事会或股东大会对授信额度重新审议。 深圳市昌红科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日、 2024 年 5 月 20 日分别召开了六届董事会第八次会议、2023 年年度股东大会，会 议审议通过了《关于公司及子公司向金融机构申请综合授信额度及对外担保额度 预计的议案》，同意公司及子公司向银行等金融机构申请总额不超过人民币 80,000.00 万元综合授信额度，授信品种包括但不限于流动资金贷款、固定资产 贷款、项目贷 ...